The nuclear FGFR1 can also promote the transcription of ER-targeting genes and cell proliferation; thus, FGFR inhibitor plus fluvestrant show potent anti-tumor effect in ER-positive and FGFR1-amplified cancer cells (22). This evidence concerns the gene FGFR1 and neoplasm.